BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mandorfer M, Reiberger T. Beta blockers and cirrhosis, 2016. Dig Liver Dis. 2017;49:3-10. [PMID: 27717792 DOI: 10.1016/j.dld.2016.09.013] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 Hofer BS, Simbrunner B, Bauer DJM, Paternostro R, Schwabl P, Scheiner B, Semmler G, Hartl L, Jachs M, Datterl B, Staettermayer AF, Trauner M, Mandorfer M, Reiberger T. Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis. Hepatol Commun 2022. [PMID: 35808889 DOI: 10.1002/hep4.2021] [Reference Citation Analysis]
2 Mao G, Li C, Wang H, Jv YH, Zhang Y, Liu L, Tang M. Exploration on the Effect of Nonselective β-Receptor Blockers (NSBBs) on Hemodynamic Parameters in Complicated Liver Cirrhosis. BioMed Research International 2022;2022:1-8. [DOI: 10.1155/2022/7922906] [Reference Citation Analysis]
3 Paternostro R, Becker J, Hofer BS, Panagl V, Schiffke H, Simbrunner B, Semmler G, Schwabl P, Scheiner B, Bucsics T, Bauer D, Binter T, Trauner M, Mandorfer M, Reiberger T. The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. Dig Liver Dis 2021:S1590-8658(21)00778-7. [PMID: 34799282 DOI: 10.1016/j.dld.2021.09.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Jachs M, Hartl L, Schaufler D, Desbalmes C, Simbrunner B, Eigenbauer E, Bauer DJM, Paternostro R, Schwabl P, Scheiner B, Bucsics T, Stättermayer AF, Pinter M, Trauner M, Mandorfer M, Reiberger T. Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. Gut 2021;70:1758-67. [PMID: 33199442 DOI: 10.1136/gutjnl-2020-322712] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 19.0] [Reference Citation Analysis]
5 Jachs M, Reiberger T, Mandorfer M. Reply. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00908-3. [PMID: 34454102 DOI: 10.1016/j.cgh.2021.08.028] [Reference Citation Analysis]
6 Gupta K, Bhurwal A, Law C, Ventre S, Minacapelli CD, Kabaria S, Li Y, Tait C, Catalano C, Rustgi VK. Acute kidney injury and hepatorenal syndrome in cirrhosis. World J Gastroenterol 2021; 27(26): 3984-4003 [PMID: 34326609 DOI: 10.3748/wjg.v27.i26.3984] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Simbrunner B, Trauner M, Reiberger T, Mandorfer M. Recent advances in the understanding and management of hepatorenal syndrome. Fac Rev 2021;10:48. [PMID: 34131658 DOI: 10.12703/r/10-48] [Reference Citation Analysis]
8 Semmler G, Binter T, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, Gavasso S, Chromy D, Bauer DJM, Simbrunner B, Scheiner B, Bucsics T, Stättermayer AF, Pinter M, Steindl-Munda P, Schöfl R, Russo FP, Simioni P, Trauner M, Ferenci P, Reiberger T, Mandorfer M. Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. Hepatology 2021;73:1275-89. [PMID: 32659847 DOI: 10.1002/hep.31462] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
9 Mandorfer M, Simbrunner B. Prevention of First Decompensation in Advanced Chronic Liver Disease. Clin Liver Dis 2021;25:291-310. [PMID: 33838851 DOI: 10.1016/j.cld.2021.01.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
10 Pfisterer N, Schmidbauer C, Riedl F, Maieron A, Stadlbauer V, Hennlich B, Schwarzer R, Puespoek A, Bucsics T, Effenberger M, Bota S, Gschwantler M, Peck-Radosavljevic M, Mandorfer M, Madl C, Trauner M, Reiberger T. Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria. Wien Klin Wochenschr. 2021;133:421-431. [PMID: 33270161 DOI: 10.1007/s00508-020-01769-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Costa D, Simbrunner B, Jachs M, Hartl L, Bauer D, Paternostro R, Schwabl P, Scheiner B, Stättermayer AF, Pinter M, Trauner M, Mandorfer M, Reiberger T. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality.J Hepatol. 2021;74:819-828. [PMID: 33075344 DOI: 10.1016/j.jhep.2020.10.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 30] [Article Influence: 6.5] [Reference Citation Analysis]
12 Garbuzenko DV, Arefyev NO. Primary prevention of bleeding from esophageal varices in patients with liver cirrhosis: An update and review of the literature. J Evid Based Med 2020;13:313-24. [PMID: 33037792 DOI: 10.1111/jebm.12407] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
13 Uschner FE, Glückert K, Paternostro R, Gnad T, Schierwagen R, Mandorfer M, Magdaleno F, Ortiz C, Schwarzkopf K, Kamath PS, Alessandria C, Boesecke C, Pfeifer A, Reiberger T, Kreisel W, Sauerbruch T, Ferlitsch A, Trebicka J, Klein S. Combination of phosphodiesterase-5-inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunction. Liver Int 2020;40:2228-41. [PMID: 32627946 DOI: 10.1111/liv.14586] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
14 Mandorfer M, Hernández-Gea V, García-Pagán JC, Reiberger T. Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review. Semin Liver Dis 2020;40:240-55. [PMID: 32557480 DOI: 10.1055/s-0040-1708806] [Cited by in Crossref: 10] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
15 Marasco G, Dajti E, Ravaioli F, Alemanni LV, Capuano F, Gjini K, Colecchia L, Puppini G, Cusumano C, Renzulli M, Golfieri R, Festi D, Colecchia A. Spleen stiffness measurement for assessing the response to β-blockers therapy for high-risk esophageal varices patients. Hepatol Int 2020;14:850-7. [PMID: 32557193 DOI: 10.1007/s12072-020-10062-w] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
16 Udumyan R, Montgomery S, Duberg AS, Fang F, Valdimarsdottir U, Ekbom A, Smedby KE, Fall K. Beta-adrenergic receptor blockers and liver cancer mortality in a national cohort of hepatocellular carcinoma patients. Scand J Gastroenterol 2020;55:597-605. [PMID: 32412855 DOI: 10.1080/00365521.2020.1762919] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
17 Mandorfer M, Kozbial K, Schwabl P, Chromy D, Semmler G, Stättermayer AF, Pinter M, Hernández-Gea V, Fritzer-Szekeres M, Steindl-Munda P, Trauner M, Peck-Radosavljevic M, García-Pagán JC, Ferenci P, Reiberger T. Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. Hepatology 2020;71:1023-36. [PMID: 31365764 DOI: 10.1002/hep.30885] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 35.0] [Reference Citation Analysis]
18 Magaz M, Baiges A, Hernández-Gea V. Precision medicine in variceal bleeding: Are we there yet? J Hepatol. 2020;72:774-784. [PMID: 31981725 DOI: 10.1016/j.jhep.2020.01.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
19 Bultas AC, Teshome B, Richter SK, Schafers S, Cooke E, Call WB. Use of Nonselective β-Blockers in Patients With End-Stage Liver Disease and Select Complications. Ann Pharmacother 2020;54:583-93. [DOI: 10.1177/1060028019893092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Mandorfer M, Reiberger T. Editorial: pressure to close the therapeutic window of non-selective beta blockers? Aliment Pharmacol Ther 2019;50:957-8. [PMID: 31591778 DOI: 10.1111/apt.15472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Facciorusso A, Antonino M, Orsitto E, Sacco R. Primary and secondary prophylaxis of spontaneous bacterial peritonitis: current state of the art. Expert Rev Gastroenterol Hepatol 2019;13:751-9. [PMID: 31304804 DOI: 10.1080/17474124.2019.1644167] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
22 He L, Ye X, Ma J, Li P, Jiang Y, Hu J, Yang J, Zhou Y, Liang X, Lin Y, Wei H. Antiviral therapy reduces rebleeding rate in patients with hepatitis B-related cirrhosis with acute variceal bleeding after endotherapy. BMC Gastroenterol 2019;19:101. [PMID: 31226942 DOI: 10.1186/s12876-019-1020-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
23 Mandorfer M, Hernández-gea V, Reiberger T, García-pagán JC. Hepatic Venous Pressure Gradient Response in Non-Selective Beta-Blocker Treatment—Is It Worth Measuring? Curr Hepatology Rep 2019;18:174-86. [DOI: 10.1007/s11901-019-00469-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
24 Kockerling D, Nathwani R, Forlano R, Manousou P, Mullish BH, Dhar A. Current and future pharmacological therapies for managing cirrhosis and its complications. World J Gastroenterol 2019; 25(8): 888-908 [PMID: 30833797 DOI: 10.3748/wjg.v25.i8.888] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
25 Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle-Bladou C, Dao T, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Hillaire S, Di Martino V, Sutton A, Audureau E, Roudot-Thoraval F, Nahon P; ANRS CO12 CirVir group. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy. Gastroenterology 2019;156:997-1009.e5. [PMID: 30768988 DOI: 10.1053/j.gastro.2018.11.053] [Cited by in Crossref: 50] [Cited by in F6Publishing: 59] [Article Influence: 16.7] [Reference Citation Analysis]
26 Lin TC, Chang WL. Multifocal gastrointestinal varices: a rare manifestation of immunoglobulin G4-related disease. Postgrad Med 2019;131:176-81. [PMID: 30632442 DOI: 10.1080/00325481.2019.1568018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
27 Piyachaturawat P, Siramolpiwat S, Sonsiri K, Tangkijvanich P, Treeprasertsuk S. Changes in transient elastography in early cirrhotic patients after receiving nonselective B-blocker for primary variceal bleeding prophylaxis: Three-month follow up. JGH Open 2018;2:172-7. [PMID: 30483585 DOI: 10.1002/jgh3.12063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Reiberger T, Bucsics T, Paternostro R, Pfisterer N, Riedl F, Mandorfer M. Small Esophageal Varices in Patients with Cirrhosis-Should We Treat Them? Curr Hepatol Rep. 2018;17:301-315. [PMID: 30546995 DOI: 10.1007/s11901-018-0420-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
29 Kim HY, So YH, Kim W, Ahn DW, Jung YJ, Woo H, Kim D, Kim MY, Baik SK. Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices. J Hepatol 2019;70:412-22. [PMID: 30389550 DOI: 10.1016/j.jhep.2018.10.018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
30 Piecha F, Mandorfer M, Peccerella T, Ozga A, Poth T, Vonbank A, Seitz HK, Rausch V, Reiberger T, Mueller S. Pharmacological decrease of liver stiffness is pressure-related and predicts long-term clinical outcome. American Journal of Physiology-Gastrointestinal and Liver Physiology 2018;315:G484-94. [DOI: 10.1152/ajpgi.00392.2017] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 6.8] [Reference Citation Analysis]
31 Scheiner B, Steininger L, Semmler G, Unger LW, Schwabl P, Bucsics T, Paternostro R, Ferlitsch A, Trauner M, Reiberger T, Mandorfer M. Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease. Liver Int 2019;39:127-35. [PMID: 30107095 DOI: 10.1111/liv.13943] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
32 Unger LW, Berlakovich GA, Trauner M, Reiberger T. Management of portal hypertension before and after liver transplantation. Liver Transpl. 2018;24:112-121. [PMID: 28752925 DOI: 10.1002/lt.24830] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
33 Mandorfer M, Scheiner B, Stättermayer AF, Schwabl P, Paternostro R, Bauer D, Schaefer B, Zoller H, Peck-Radosavljevic M, Trauner M, Reiberger T, Ferenci P, Ferlitsch A. Impact of patatin-like phospholipase domain containing 3 rs738409 G/G genotype on hepatic decompensation and mortality in patients with portal hypertension. Aliment Pharmacol Ther 2018;48:451-9. [PMID: 29956823 DOI: 10.1111/apt.14856] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
34 Sauerbruch T, Schierwagen R, Trebicka J. Managing portal hypertension in patients with liver cirrhosis. F1000Res 2018;7:F1000 Faculty Rev-533. [PMID: 29780579 DOI: 10.12688/f1000research.13943.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
35 Schwarzer R, Kivaranovic D, Paternostro R, Mandorfer M, Reiberger T, Trauner M, Peck-Radosavljevic M, Ferlitsch A. Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study. Aliment Pharmacol Ther. 2018;47:1162-1169. [PMID: 29492989 DOI: 10.1111/apt.14576] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
36 Yao H, Zhang C. Angiotensin II receptor blockers for the treatment of portal hypertension in patients with liver cirrhosis: a systematic review and meta-analysis of randomized controlled trials. Ir J Med Sci 2018;187:925-34. [DOI: 10.1007/s11845-018-1765-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
37 Paternostro R, Heinisch BB, Reiberger T, Mandorfer M, Schwarzer R, Seeland B, Trauner M, Peck-Radosavljevic M, Ferlitsch A. Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. Liver Int 2018;38:1427-36. [PMID: 29368385 DOI: 10.1111/liv.13704] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
38 Bucsics T, Schoder M, Diermayr M, Feldner-Busztin M, Goeschl N, Bauer D, Schwabl P, Mandorfer M, Angermayr B, Cejna M, Ferlitsch A, Sieghart W, Trauner M, Peck-Radosavljevic M, Karner J, Karnel F, Reiberger T. Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding - A two decades experience. PLoS One 2018;13:e0189414. [PMID: 29315304 DOI: 10.1371/journal.pone.0189414] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
39 Mandorfer M, Reiberger T. Role of diuretics in the harmful effects of beta blockers in patients with ascites. Author’s reply. Digestive and Liver Disease 2018;50:102-3. [DOI: 10.1016/j.dld.2017.09.135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Bucsics T, Schoder M, Goeschl N, Schwabl P, Mandorfer M, Diermayr M, Feldner M, Riedl F, Bauer D, Angermayr B, Cejna M, Ferlitsch A, Sieghart W, Trauner M, Peck-radosavljevic M, Karner J, Karnel F, Reiberger T. Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice. Digestive and Liver Disease 2017;49:1360-7. [DOI: 10.1016/j.dld.2017.08.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
41 Schwarzer R, Kivaranovic D, Mandorfer M, Paternostro R, Wolrab D, Heinisch B, Reiberger T, Ferlitsch M, Gerner C, Trauner M, Peck-radosavljevic M, Ferlitsch A. Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension. Aliment Pharmacol Ther 2018;47:86-94. [DOI: 10.1111/apt.14377] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
42 Reiberger T, Püspök A, Schoder M, Baumann-Durchschein F, Bucsics T, Datz C, Dolak W, Ferlitsch A, Finkenstedt A, Graziadei I, Hametner S, Karnel F, Krones E, Maieron A, Mandorfer M, Peck-Radosavljevic M, Rainer F, Schwabl P, Stadlbauer V, Stauber R, Tilg H, Trauner M, Zoller H, Schöfl R, Fickert P. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). Wien Klin Wochenschr 2017;129:135-58. [PMID: 29063233 DOI: 10.1007/s00508-017-1262-3] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 12.4] [Reference Citation Analysis]
43 Kumar P. Role of diuretics in the harmful effects of beta blockers in patients with ascites. Dig Liver Dis 2018;50:101-2. [PMID: 28967631 DOI: 10.1016/j.dld.2017.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
44 Mandorfer M, Reiberger T. Reply to: "Non selective beta blockers in cirrhosis". J Hepatol 2017;67:1343-4. [PMID: 28789883 DOI: 10.1016/j.jhep.2017.07.018] [Reference Citation Analysis]
45 Møller S, Hove JD. Assessment of systolic function in the evaluation of patients with cirrhosis. Hepatology 2017;65:1799-802. [PMID: 28317147 DOI: 10.1002/hep.29163] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
46 Bucsics T, Krones E. Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome. Gastroenterol Rep (Oxf). 2017;5:127-137. [PMID: 28533910 DOI: 10.1093/gastro/gox009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
47 Schwabl P, Laleman W. Novel treatment options for portal hypertension. Gastroenterol Rep (Oxf). 2017;5:90-103. [PMID: 28533907 DOI: 10.1093/gastro/gox011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
48 Haq I, Tripathi D. Recent advances in the management of variceal bleeding. Gastroenterol Rep (Oxf)5:113-126. [PMID: 28533909 DOI: 10.1093/gastro/gox007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 5.6] [Reference Citation Analysis]